Adjuvant FOLFOXIRI for High-risk Stage III Colon Cancer
Status:
Recruiting
Trial end date:
2028-03-15
Target enrollment:
Participant gender:
Summary
A multicenter, open labeled randomized, phase II trial comparing FOLFOXIRI and mFOLFOX6 as
adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer